Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of endogenous GIP in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mechanisms in Endocrinology: FXR signalling - a novel target in metabolic diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hepatic microbiome in healthy lean and obese humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In 2008, the first evidence of a new hormone called neuronostatin was published. The hormone was discovered using a bioinformatic method and found to originate from the same preprohormone as somatostatin. This small peptide hormone of 13 amino acids and a C-terminal amidation was soon found to exert pleiotropic physiological effects. In animal studies, neuronostatin has been shown to reduce food intake and delay gastric emptying and gastrointestinal transit. Furthermore, neuronostatin has been shown to affect glucose metabolism by increasing glucagon secretion during situations when glucose concentrations are low. Additionally, neuronostatin has been shown to affect neural tissue and cardiomyocytes by suppressing cardiac contractility. The effects of neuronostatin have not yet been delineated in humans, but if the effects found in animal studies translate to humans it could position neuronostatin as a promising target in the treatment of obesity, hypertension and diabetes. In this review, we describe the discovery of neuronostatin and the current understanding of its physiological role and potential therapeutic applicability.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind185
Udgave nummer4
Sider (fra-til)R93-R101
ISSN0804-4643
DOI
StatusUdgivet - 1 sep. 2021

ID: 67568344